National Cancer Institute Grants $3M to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer

The National Institutes of Health’s National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate a Phase II clinical trial for the investigational drug, DDFPe, in the brain cancer, glioblastoma multiforme (GBM).


Link to press release...